90 related articles for article (PubMed ID: 11345646)
1. Cytocidal effect and DNA damage of nedaplatin in vitro by simulating pharmacokinetic parameters.
Kawanishi K; Miyagi Y; Yamamoto J; Miyagi Y; Nakamura K; Kodama J; Hongo A; Yoshinouchi M; Kudo T
Cancer Chemother Pharmacol; 2001 Apr; 47(4):303-8. PubMed ID: 11345646
[TBL] [Abstract][Full Text] [Related]
2. Cytocidal effect and DNA damage of nedaplatin: a mathematical model and analysis of experimental data.
Miyagi Y; Kawanishi K; Miyagi Y; Yamada S; Yamamoto J; Kodama J; Hongo A; Yoshinouchi M; Kudo T
Cancer Chemother Pharmacol; 2001 Mar; 47(3):229-35. PubMed ID: 11320666
[TBL] [Abstract][Full Text] [Related]
3. Effect of cisplatin on cell death and DNA crosslinking in rat mammary. Adenocarcinoma in vitro.
Yamamoto J; Miyagi Y; Kawanishi K; Yamada S; Miyagi Y; Kodama J; Yoshinouchi M; Kudo T
Acta Med Okayama; 1999 Oct; 53(5):201-8. PubMed ID: 10561728
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma.
Niioka T; Uno T; Yasui-Furukori N; Takahata T; Shimizu M; Sugawara K; Tateishi T
Cancer Chemother Pharmacol; 2007 Apr; 59(5):575-80. PubMed ID: 16912889
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxicity, DNA strand breakage and DNA-protein crosslinking by a novel transplatinum compound in human A2780 ovarian and MCF-7 breast carcinoma cells.
Farrell N; Povirk LF; Dange Y; DeMasters G; Gupta MS; Kohlhagen G; Khan QA; Pommier Y; Gewirtz DA
Biochem Pharmacol; 2004 Sep; 68(5):857-66. PubMed ID: 15294448
[TBL] [Abstract][Full Text] [Related]
6. Determination of optimal dosage for nedaplatin based on pharmacokinetic and toxicodynamic analysis.
Ishibashi T; Yano Y; Oguma T
Anticancer Res; 2005; 25(2B):1273-81. PubMed ID: 15865078
[TBL] [Abstract][Full Text] [Related]
7. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers.
Alberts DS; Fanta PT; Running KL; Adair LP; Garcia DJ; Liu-Stevens R; Salmon SE
Cancer Chemother Pharmacol; 1997; 39(6):493-7. PubMed ID: 9118460
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of serum platinum of gynecologic cancer patients treated with nedaplatin.
Matsumoto Y; Ishiko O; Nakagawa E; Sumi T; Hyun Y; Ando Y; Ogita S
Oncol Rep; 2001; 8(6):1269-73. PubMed ID: 11605047
[TBL] [Abstract][Full Text] [Related]
9. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
10. In vitro cytotoxicity, pharmacokinetics and ex vivo pharmacodynamics of a new platinum compound, cis-malonato [(4R,5R-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclopentane] platinum (II).
Kim DK; Kim HT; Cho YB; Kim TS; Kim KH; Hong WS
Anticancer Res; 1996; 16(1):251-6. PubMed ID: 8615617
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
[TBL] [Abstract][Full Text] [Related]
12. A formula for predicting optimal dosage of nedaplatin based on renal function in adult cancer patients.
Ishibashi T; Yano Y; Oguma T
Cancer Chemother Pharmacol; 2002 Sep; 50(3):230-6. PubMed ID: 12203105
[TBL] [Abstract][Full Text] [Related]
13. Chemosensitivity testing of a novel platinum analog, nedaplatin (254-S), in human gynecological carcinomas: a comparison with cisplatin.
Koshiyama M; Kinezaki M; Uchida T; Sumitomo M
Anticancer Res; 2005; 25(6C):4499-502. PubMed ID: 16334133
[TBL] [Abstract][Full Text] [Related]
14. Combination of nedaplatin and vindesine for treatment of relapsed or refractory non-small-cell lung cancer.
Takigawa N; Segawa Y; Ueoka H; Kiura K; Tabata M; Shibayama T; Takata I; Miyamoto H; Eguchi K; Harada M
Cancer Chemother Pharmacol; 2000; 46(4):272-8. PubMed ID: 11052624
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity study with bioreductive benzoquinone alkylating agents: effects on DT-diaphorase-mediated DNA crosslink and strand break formation in relation to mechanisms of cytotoxicity.
Fourie J; Guziec F; Guziec L; Monterrosa C; Fiterman DJ; Begleiter A
Cancer Chemother Pharmacol; 2004 Mar; 53(3):191-203. PubMed ID: 14614574
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system.
Kishi S; Goto N; Nakamura T; Ueda T
Cancer Res; 1999 Jun; 59(11):2629-34. PubMed ID: 10363985
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients.
Ishibashi T; Yano Y; Oguma T
Br J Clin Pharmacol; 2003 Aug; 56(2):205-13. PubMed ID: 12895194
[TBL] [Abstract][Full Text] [Related]
19. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers.
Monk BJ; Alberts DS; Burger RA; Fanta PT; Hallum AV; Hatch KD; Salmon SE
Gynecol Oncol; 1998 Nov; 71(2):308-12. PubMed ID: 9826477
[TBL] [Abstract][Full Text] [Related]
20. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
